CanaQuest Bolsters Team for CQ-001 Trials
By Patricia Miller
Jun 12, 2024
CanaQuest Medical (OTC: CANQF) adds experts to advance CQ-001 through clinical trials for FDA approval in epilepsy.
Drug discovery
Related Articles:
- • Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
- • Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
- • Roche (RHHBY): Significant U.S. Investment to Enhance Manufacturing and Innovation
- • Eli Lilly and Co (NYSE:LLY): Promising Breakthrough in Weight-Loss Treatments
Explore more on these topics:
Important Notice And Disclaimer
This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.